Mark Lupher's most recent trade in Adverum Biotechnologies Inc was a trade of 10,520 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 17, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Adverum Biotechnologies Inc | Mark Lupher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 10,520 | 10,520 | - | - | Stock Option (Right to Buy) | |
Adverum Biotechnologies Inc | Mark Lupher | Director | Purchase of securities on an exchange or from another person at price $ 1.35 per share. | 07 Feb 2024 | 130,000 | 130,000 (0%) | 0% | 1.4 | 175,500 | Common Stock |
Adverum Biotechnologies Inc | Mark Lupher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
Adverum Biotechnologies Inc | Mark Lupher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
Adverum Biotechnologies Inc | Mark Lupher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) |